SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00460 SIHUAN PHARM

Market Closed 07-24 16:08:05

0.880

-0.020

-2.22%

High0.890	Low0.870	Vol9.81M
Open0.890	D1 Closing0.900	Amplitude2.22%
Mkt Cap8.03B	Tradable Cap8.03B	Total Shares9.13B
T/O8.63M	T/O Rate0.11%	Tradable Shares9.13B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"SIHUAN PHARM","latestPrice":0.88,"timestamp":1784880485002,"preClose":0.9,"halted":0,"volume":9812000,"delay":0,"changeRate":-0.02222222222222224,"floatShares":9126000000,"shares":9126000000,"eps":0.02281733207857899,"marketStatus":"Market Closed","change":-0.02,"latestTime":"07-24 16:08:05","open":0.89,"high":0.89,"low":0.87,"amount":8625560,"amplitude":0.022222,"askPrice":0.88,"askSize":1816000,"bidPrice":0.87,"bidSize":1578000,"shortable":3,"etf":0,"ttmEps":0.02281617383837196,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":0.9,"dividendRate":0.025538,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.41149,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2652377251","title":"Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2652377251","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652377251?lang=en_us&edition=fundamental","pubTime":"2026-07-19 18:49","pubTimestamp":1784458150,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration awardXuanzhu Biopharmaceutical received a final CIETAC arbitration award on July 15, 2026 over a May 21, 2021 technology transfe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nNDL9lltbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1593","BK1515","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123722699","title":"SIHUAN PHARM Shares Surge Over 12% in Early Trading Following Publication of Key Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1123722699","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123722699?lang=en_us&edition=fundamental","pubTime":"2026-07-14 11:20","pubTimestamp":1783999229,"startTime":"0","endTime":"0","summary":"Shares of SIHUAN PHARM (00460) surged more than 12% during the morning session. At the time of writing, the stock was up 8.33%, trading at HK$0.91 with a turnover of HK$51.61 million. The significant...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1600","BK1593","00460","KCAI","BK4588","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649649282","title":"Sihuan Pharma Says NMPA Accepts NDA for Anaprazole Sodium for Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649649282","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649649282?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:19","pubTimestamp":1783322375,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::*NMPA ACCEPTS NDA FOR ANAPRAZOLE SODIUM FOR REFLUX ESOPHAGITIS*Further company coverage: 0460.HK* ((Reuters.Briefs@thomsonreuter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSDdv03m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1593","BK1600","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648047665","title":"Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Pricey","url":"https://stock-news.laohu8.com/highlight/detail?id=2648047665","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648047665?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:34","pubTimestamp":1783078455,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that the first patient has been enrolled in a Phase III trial for Anaprazole Sodium Enteric-coated Tablets in Helicobacter pylori treatment, a development that could influence how investors view the stock.\nSee our latest analysis for Sihuan Pharmaceutical Holdings Group.\nAt a share price of HK$0.89, Sihuan Pharmaceutical Holdings Group has seen a 7-day share price return of 7.23%, but the 90-day share price return is down...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/sihuan-pharmaceutical-holdings-group-sehk460-following-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/sihuan-pharmaceutical-holdings-group-sehk460-following-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK1600","BK1593","PRGS","BK4097","III","LU2065732104.USD","BK1515","00460","BK1191","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647874285","title":"Sihuan Pharmaceutical Unit's Reflux Esophagitis Drug Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2647874285","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647874285?lang=en_us&edition=fundamental","pubTime":"2026-06-30 14:24","pubTimestamp":1782800672,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical's  new drug application for the new indication of Anaprazole Sodium Enteric-coated Tablets was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The acceptance is for the drug, developed by Xuanzhu Biopharmaceutical, a unit of the company, to treat adult reflux esophagitis.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK1600","BK1191","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135136193","title":"NMPA Accepts Sihuan Pharmaceutical Subsidiary Xuanzhu Biopharm’s NDA for Anaprazole Sodium in Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1135136193","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135136193?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:43","pubTimestamp":1782794608,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical”) reported that China’s National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581790","title":"Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581790","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647581790?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792352,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisXuanzhu Biopharmaceutical’s NMPA accepted an NDA for anaprazole sodium enteric-coated tablets to treat adult reflux e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2BC18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1593","BK1515","00460","02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176409937","title":"Sihuan Pharmaceutical AGM Clears All Resolutions; Final Dividend Set at HK1.09 Cents per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1176409937","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176409937?lang=en_us&edition=fundamental","pubTime":"2026-06-26 17:06","pubTimestamp":1782464768,"startTime":"0","endTime":"0","summary":"On 26 June 2026, Sihuan Pharmaceutical Holdings Group Ltd. held its annual general meeting, where shareholders approved every resolution put forward, including a cash dividend, director re-elections,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333010","title":"Sihuan Pharmaceutical Shareholders Approve RMB 0.96 Cent Final Dividend for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333010","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646333010?lang=en_us&edition=fundamental","pubTime":"2026-06-26 16:43","pubTimestamp":1782463389,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical shareholders approve RMB 0.96 cent final dividend for 2025Sihuan Pharmaceutical held its annual general meeting on June 26, 2026, with all resolutions passed.Shareholders adopted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL1BLlsC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","00460","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147951817","title":"Sihuan Pharmaceutical launches Phase III trial of Anaprazole Sodium for Helicobacter pylori eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=1147951817","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147951817?lang=en_us&edition=fundamental","pubTime":"2026-06-22 13:04","pubTimestamp":1782104655,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. reported that its non-wholly-owned subsidiary, Xuanzhu Biopharm, has enrolled the first patient in a Phase III, multi-centre, randomised, double-blind,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645628097","title":"Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2645628097","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645628097?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:05","pubTimestamp":1782036350,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical enrolled the first patient in a Phase III trial of anaprazole sodium in Helicobacter pylori eradication therapy.Trial results have not been presented; the study will assess whether the regimen can clear infection safely versus an esomeprazole-based comparator.The study targets 556 adults across multiple centers with a 14-day treatment course.Anaprazole sodium is already marketed in China for duodenal ulcer; success could broaden its label and support faster commercial uptake.The company cited China’s H. pylori drug market at RMB 5.5 billion in 2024, projecting RMB 6.8 billion in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL8bPT69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1515","BK1593","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702139","title":"Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702139?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778311,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical filed an updated list of directors with the Hong Kong Stock Exchange on June 18, 2026.Xu Yanjun remains chairperson of the board, also serving as general manager.The board comprises executive, non-executive, employee representative, and independent non-executive directors; key committee chairs are held by independent directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbTRqvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","02575","BK1191","BK1515","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644611702","title":"Xuanzhu Biopharma names Yue Xin employee representative director after election","url":"https://stock-news.laohu8.com/highlight/detail?id=2644611702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644611702?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:21","pubTimestamp":1781778080,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical named Yue Xin as employee representative director, effective June 18, 2026.Yue replaces an executive director seat as the board shifts its composition.Li Jia Kui’s resignation as executive director takes effect immediately on Yue’s appointment.Yue served as a company supervisor from November 2021 to June 2026.She joined the group in 2019, rising from administrative assistant to head of administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbVnXtt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1515","BK1593","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144599537","title":"SIHUAN PHARM Purchases 5 Million Shares for Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1144599537","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144599537?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:44","pubTimestamp":1780919054,"startTime":"0","endTime":"0","summary":"On June 8, 2026, the trustee for SIHUAN PHARM (00460)'s 2022 share incentive plan acquired a total of 5 million company shares from the open market.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1515","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154080359","title":"Sihuan Pharmaceutical Buys 5.00 Million Shares for Award Scheme After 37.7% Revenue Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1154080359","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154080359?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:42","pubTimestamp":1780918976,"startTime":"0","endTime":"0","summary":"On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106281238","title":"SIHUAN PHARM Purchases 10 Million Shares for Incentive Scheme via Trustee","url":"https://stock-news.laohu8.com/highlight/detail?id=1106281238","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106281238?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:05","pubTimestamp":1780488314,"startTime":"0","endTime":"0","summary":"According to an announcement, on June 3, 2026, the trustee for SIHUAN PHARM's (00460) share incentive scheme purchased a total of 10 million shares of the company in the market.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1593","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901821","title":"Sihuan Pharma trustee buys 10 million shares for employee share award scheme at HK$0.95 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901821","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901821?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:53","pubTimestamp":1780487625,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical’s trustee bought 10,000,000 shares on June 3, 2026 under the 2022 share award scheme.Average purchase price about HK$ 0.95 per share.Shares bought equal roughly 0.11% of issued shares, excluding treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL2q03FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1593","BK1515","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199049822","title":"Sihuan Pharma Publishes AGM Circular and Switches to E-Communication for Non-Registered Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=1199049822","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199049822?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:45","pubTimestamp":1780389906,"startTime":"0","endTime":"0","summary":"On 3 June 2026, Sihuan Pharmaceutical Holdings Group Ltd. released its latest Annual General Meeting circular, now accessible in both English and Chinese through the company’s website...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194144049","title":"Sihuan Pharma Releases AGM Circular and Proxy Form; Shareholders May Update Communication Preferences","url":"https://stock-news.laohu8.com/highlight/detail?id=1194144049","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194144049?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:44","pubTimestamp":1780389861,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Holdings Group Ltd. announced on 3 June 2026 that the English and Chinese versions of its latest Annual General Meeting circular and proxy form have been uploaded to both the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640991592","title":"Sihuan Pharmaceutical announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640991592","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640991592?lang=en_us&edition=fundamental","pubTime":"2026-06-02 16:31","pubTimestamp":1780389086,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical will hold its annual general meeting in Shenzhen on June 26, 2026.Shareholders will vote on fresh mandates to issue shares up to 20% and repurchase shares up to 10%.A final cash dividend of RMB 0.96 cents per share for the year ended Dec. 31, 2025 is slated for approval.Other items include director re-elections, auditor re-appointment, and adoption of a 2026 share incentive scheme with a 10% share cap.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 02, 2026, and is solely responsible for the information contained ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL43bNyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1600","BK1515","BK1593","00460"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.0244},{"period":"3month","weight":-0.3252},{"period":"6month","weight":-0.3353},{"period":"1year","weight":-0.3303},{"period":"ytd","weight":-0.2757}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119713},{"month":2,"riseRate":0.5,"avgChangeRate":0.000651},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.032043},{"month":4,"riseRate":0.533333,"avgChangeRate":0.038601},{"month":5,"riseRate":0.4,"avgChangeRate":0.003084},{"month":6,"riseRate":0.533333,"avgChangeRate":-0.005353},{"month":7,"riseRate":0.6,"avgChangeRate":0.01117},{"month":8,"riseRate":0.5,"avgChangeRate":-0.014605},{"month":9,"riseRate":0.214286,"avgChangeRate":-0.045139},{"month":10,"riseRate":0.571429,"avgChangeRate":0.02973},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008336},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017751}],"exchange":"SEHK","name":"SIHUAN PHARM","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SIHUAN PHARM(00460) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SIHUAN PHARM,00460,SIHUAN PHARM股票,SIHUAN PHARM股票老虎,SIHUAN PHARM股票老虎国际,SIHUAN PHARM行情,SIHUAN PHARM股票行情,SIHUAN PHARM股价,SIHUAN PHARM股市,SIHUAN PHARM股票价格,SIHUAN PHARM股票交易,SIHUAN PHARM股票购买,SIHUAN PHARM股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SIHUAN PHARM(00460),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SIHUAN PHARM(00460) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}